Actively Recruiting
CD147 Targeting Nanobody Probe for PET Imaging in Solid Tumors
Led by Hua Zhu · Updated on 2024-12-05
30
Participants Needed
1
Research Sites
104 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The objective of the study is to construct a noninvasive approach using 68Ga-NOTA-MAL-NB147 PET/CT to detect the CD147 expression of tumor lesions in patients with Solid tumors and to identify patients benefiting from CD147 targeting treatment.
CONDITIONS
Official Title
CD147 Targeting Nanobody Probe for PET Imaging in Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histopathologically or cytologically confirmed malignant melanoma, hepatocellular carcinoma, colorectal cancer, pancreatic cancer, breast cancer, gastric cancer, or lung cancer
- Aged 18 to 75 years, any gender
- ECOG performance score of 0 or 1
- Expected survival time of at least 6 months
- At least one easily accessible lesion that can be biopsied within one month before or after the PET scan, with consent to use biopsy tissue for analysis
- Blood routine and liver/kidney function within specified limits: WBC 4.0x10^9/L or neutrophils 1.5x10^9/L, PLT 100x10^9/L, Hb 90 g/L; PT or APTT 1.5 ULN; T-Bil 1.5xULN, ALT/AST 2.5xULN (or 5xULN with liver metastases), ALP 2.5xULN (or 4.5xULN with bone or liver metastases); BUN 1.5xULN; SCr 1.5xULN
- At least one measurable target lesion according to RECIST 1.1 criteria
- Women must use contraceptive measures during the study and for six months after; men must agree to contraception during the study and for six months after
- Able to understand and voluntarily sign informed consent with good compliance
You will not qualify if you...
- Pregnant or breastfeeding women, or women planning pregnancy during the study or within three months after administration; individuals donating sperm or oocytes
- Known or suspected allergy to the investigational drug or its components
- Significant liver or kidney dysfunction: TBIL > 1.5 x 20 �b5mol/L, AST > 2.5 x 45 �b5mol/L, ALT > 2.5 x 40 �b5mol/L, or serum creatinine > 1.5 x 130 �b5mol/L
- Unable to cooperate with PET scan due to claustrophobia or other conditions
- Other conditions deemed inappropriate for participation by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Beijing Cancer Hospital
Beijing, Beijing Municipality, China, 100142
Actively Recruiting
Research Team
H
Hua Zhu
CONTACT
Z
Zhi Yang
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here